On September 28, WUXI XDC fell 3.02% in regular trading, trading at HK$78.75/share, with turnover of approximately HK$32.92 million. The decline came amid broad weakness across the Life Sciences Tools & Services sector, with peers GENSCRIPT BIO down 3.63%, WUXI APPTEC down 1.72%, and WUXI BIO down 0.94%.

The selling pressure appears tied to the continued market overhang from WuXi AppTec's late-August block trade disposal of 53.524 million WUXI XDC shares at an average price of HK$73.23 per share, totaling approximately HK$3.92 billion. The transaction reduced WuXi AppTec's stake from 18.36% to 14.14%, generating an estimated pre-tax gain of RMB 3.143 billion. Meanwhile, institutional sentiment in biomedical services remains cautious, with analysts noting industry demand has yet to show clear signs of recovery.

On the positive side, Goldman Sachs recently reiterated a Buy rating with a target price of HK$97.90, citing an upcoming FDA inspection of the Wuxi production facility as a key commercial milestone. WUXI XDC's H1 results showed revenue of RMB 3.701 billion, up 37.0% year-over-year, with adjusted net profit rising 37.4% to RMB 1.027 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)